Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season

Diagnostic Microbiology and Infectious Disease

Volumn 32, Issue 2, 1998, Pages 119-126

  Jones, Ronald N ^a   Pfaller, Michael A ^a   Doern, Gary V ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBON DIOXIDE; CEFTRIAXONE; CIPROFLOXACIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; NAPHTHYRIDINE DERIVATIVE; OFLOXACIN; PENICILLIN G; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD CULTURE; CEREBROSPINAL FLUID CULTURE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BLOOD; CEREBROSPINAL FLUID; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; PHARYNX; PNEUMOCOCCAL INFECTIONS; POPULATION SURVEILLANCE; RESPIRATORY TRACT INFECTIONS; SPUTUM; STREPTOCOCCUS PNEUMONIAE;

EID: 0031789135     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00072-8     Document Type: Article

References (25)

1. Bedos J.-P., Rieux V., Bauchet J., Muffat-Joly M., Carbon C., Azoulay-Dupuis E. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother. 42:1998;862-867.
2. Bolmstrom A, Arvidson S, Ericsson M, Karlsson A (1988) Novel technique for direct quantification of antimicrobial susceptibility of microorganisms (abstr 1209). In: Program and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, p. 75.
3. Brighty K.E., Gootz T.D. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 39:(suppl B):1997;1-14.
4. Butler J.C., Hofmann J., Cetron M.S., Elliott J.A., Facklam R.R., Breiman R.F. The continued emergence of resistant Streptococcus pneumoniae in the United States an update from the Centers for Disease Control and Prevention Pneumococcal Sentinel Surveillance System . J Infect Dis. 174:1996;986-993.
5. Cutler N.R., Vincent J., Jhee S.S., Teng R., Wardle T., Lucas G., Dogolo L.C., Sramek J.J. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacine. Antimicrob Agents Chemother. 41:1997;1298-1300.
6. Edelstein P.H., Edelstein M.A., Ren J., Polzer R., Gladue R.P. Activity of trovafloxacin (CP-99,219) against Legionella Isolates in vitro activity, intracellular accumulation and killing in macrophages and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia . Antimicrob Agents Chemother. 40:1996;314-319.
7. Girard A.E., Girard D., Gootz T.D., Faiella J.A., Cimochowski C.R. In vivo efficacy of trovafloxacin (CP-99,19), a new quinolone with extended activities against Gram-positive pathogens, Streptococcus pneumoniae and Bacteroides fragilis. Antimicrob Agents Chemother. 39:1995;2210-2216.
8. Gooding B.B., Jones R.N. In vitro antimicrobial activity of CP-99,219, a novel azabicyclonaphthyridone. Antimicrob Agents Chemother. 37:1993;349-353.
9. Jones R.N. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 100:(suppl 6A):1996;3S-12S.
10. Jones R.N., Ballow C.H., Schentag J.J., Johnson D.M., Dienhart J.A. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Diagn Microbiol Infect Dis. 31:1998;313-325.
11. Jones R.N., Pfaller M.A., Doern G.V., Verhoef J., Jones M.E., Sader H.S. Initial report of longitudinal, international antimicrobial surveillance study (SENTRY): alarming resistance rates in monitored sites (68 medical centers) in the USA, Canada, South America, and Europe (abstr E-109). Proceedings of the 37th ICAAC. 1997;American Society for Microbiology, Washington, DC.
12. Kenny G.E., Cartwright R.D. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother. 40:1996;1048-1049.
13. Kim Y.S., Liu Q., Chow L.L., Tauber M.G. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 41:1997;1186-1189.
14. Klugman K., Goldstein F., Kohno S., Baquero F. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect. 3:(suppl 1):1997;S48-S60.
15. Klugman K., Gootz T.D. In vitro and in vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 39:(suppl B):1997;51-55.
16. Marriott M.S. Grepafloxacin microbiological properties . Clin Microbiol Infect. 4:(suppl 1):1998;S9-S14.
17. Morrissey I. Bactericidal activity of trovafloxacin (CP-99,219). J Antimicrob Chemother. 38:1996;1061-1066.
18. Approved Standard M7-A4 Standard Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically . 4th ed. 1997;NCCLS, Wayne, PA.
19. Performance Standards for Antimicrobial Susceptibility Testing M100-S8 . 1998;NCCLS, Wayne, PA.
20. Neu H.C., Chin N.-X. In vitro activity of the enw fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 38:1994;2615-2622.
21. Nicolau D.P., Tessier P.R., Quintiliani R., Nightingale C.H. Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities. Antimicrob Agents Chemother. 42:1998;991-992.
22. Pan X.S., Ambler J., Mehtar S., Fisher L.M. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 40:1996;2321-2326.
23. Spika J.S., Facklam R.R., Plikaytis B.D., Oxtoby M.J. Antimicrobial resistance of Streptococcus pneumoniae in the United States. J Infect Dis. 163:1991;1273-1278.
24. Teng R., Dogolo L.C., Willavize S.A., Hylar L., Friedman Vincent J. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother. 39:(suppl B):1997;87-92.
25. Thornsberry C., Ogilvie P., Kahn J., Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus penumoniae, Haemophilus influencae, and Moraxella catarrhalis in the United States in 1996-97 respiratory season. Diagn Microbiol Infect Dis. 29:1997;249-257.